TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Soft plaque ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Airway resistance at PEEPe levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pplat changes at different PEEPe levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of oocytes retrieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of high-quality embryos obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vital pregnancy rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Prostate Symptom Score System (IPSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum flow rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of reflux esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: small bowel preparation quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: detection of angioectasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Decrease in negative mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in symptoms related to stress and anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Drug-induced Extrapyramidal Symptoms Scale total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Drug Attitude Inventory score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peak cTnI at 1 hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: early postoperative cognitive decline
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: prolonged hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Serum plasma concentrations of fluoxetine and norfluoxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of the patch
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adhesiveness of the patch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bile reflux activity in the gastric pouch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: De novo reflux symptoms at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Peak inspiratory pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in apo B levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improved performance in Fitts' Law test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in throughput
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parathyroid hormone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performance times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to efficacy failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: akathisia
Endpoint domain: Adverse events/effects
Primary endpoint: serum prolactin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: nurse-observed serious errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total passive extension deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Response to treatment (PR or SD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of progression within 12 WOT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum MCP‐1, PCT, ICAM‐1, CXCL8, CRP, IFN‐γ, and IL‐17 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Peripheral blood Th1 and Th17 content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum IL‐4 and TGF‐β levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bleb survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleb score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SPID48 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery of clotting factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pulsatility Index (PI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Venous dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Pancreatitis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean peak plasma concentration (Cmax) of E-3174
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve [AUC(0-infinity)] of E-3174
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life (t1/2) of E-3174
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative analgesic consumption at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative analgesic consumption at 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appropriate use of thromboprophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Desire and sexual interest
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vaginal lubrication during coitus and/or foreplay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to reach orgasm
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: work ability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: diurnal curve pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density (BMD) changes in lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density (BMD) changes in femoral neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy failures after subsequent doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of instrumental delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Irritability scores at 1 hour of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean subject pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of treatment pauses due to discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for lidocaine 4%/benzocaine 20%
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total Blood Loss (TBL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to failure of the extensor muscle of the trunk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Urinary microalbumin excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: anti-HBs titre at 1 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anti-HBs titre at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lower extremity function improvement (walking speed)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health knowledge about hepatitis B
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Inhibition of skin reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Inhibition of blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Lipid and glycemic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Limb fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LCDS change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite of all-cause mortality, non-fatal myocardial infarction, stroke or ischaemia-driven target lesion revascularisation
Endpoint domain: Mortality/survival
Primary endpoint: Primary cesarean delivery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: VBAC rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: worst pain palliation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VBA blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Retention in care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV testing of infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Attendance at antenatal and postnatal care visits
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Percentage of subjects on inhaled corticosteroid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of emergency department visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of subjects with an asthma action plan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T-B transport
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of durable power of attorney for health care form
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of postnatal visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of women who breastfed for longer than 4 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of women who underwent blood tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gross motor capacity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: favourable clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gentamicin peak concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trough concentrations in the undesirable range
Endpoint domain: Adverse events/effects
Primary endpoint: CD3+ cells increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokine production increase (IL‐2, IL‐4, IL‐10, IFN‐gamma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IFN‐gamma/IL‐10 ratio decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Thromboxane B2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quality of life at 12-month follow-up
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Minimal clinically important difference in SSM symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal clinically important difference in SSM function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitreomacular adhesion resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean best-corrected visual acuity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAARS:Inv total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak-plasma level of metronidazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve of metronidazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of xerostomia score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of delirium
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of delirium
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of subsyndromal delirium
Endpoint domain: Adverse events/effects
Primary endpoint: vasovagal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Higher-order aberration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast sensitivity under photopic conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast sensitivity under mesopic conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: S-100B serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of PID
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severe patient-ventilator asynchrony
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ineffective efforts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: delayed cycling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endurance time (EET)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inspiratory capacity (IC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health status (St George's Respiratory Questionnaire total score)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximal expiratory pressure (PEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 5-year failure-free survival
Endpoint domain: Mortality/survival
Primary endpoint: relapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean changes in plasma total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean changes in LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean changes in triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: image testing performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hearing thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sensorineural hearing loss prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Static compliance measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ST index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left cardiac ventricular ejection time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-operative intermetatarsal angle (IMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnitude of IMA correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major adverse cardiac and cerebrovascular events (MACCE)
Endpoint domain: Adverse events/effects
Primary endpoint: Thallium severity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: P falciparum infection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prophylaxis failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: cART adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: genital tract inflammation indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with successful prophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial pressure of oxygen (PaO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Overall skills improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resident knowledge improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Provision of follow-up instructions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in pain after one week of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in S. mutans levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean IELT (Intravaginal Ejaculation Latency Time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transient hot flush reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stable hot flush reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to transient 50% reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SRI-5 response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: changes in anti-double stranded DNA antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Median decrease in FLT SUV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median decrease in FDG SUV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prescribing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean ratio of marrow doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean oxygen cost
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social network size with relatives
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: MSIS‐29, v2 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Fatigue Impact Score (physical subscale)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Six Minute Walk Test distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PGIC scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Potential fatal cancers associated with radiation exposure
Endpoint domain: Mortality/survival
Primary endpoint: Mean supine blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Median value for microalbuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Post-stroke depression (PSD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of HF hospitalization or all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Mean IOP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Percentage of eyes with IOP drop > or =20%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Mean number of medications
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinical Global Impressions-Improvement scale (CGI-I)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: serum triacylglycerol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: weight loss from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: achievement of weight loss ≥5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: WRQOL impairment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Eye tracking success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visceral fat loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: IMT (Intima-media thickness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes